MX2022011234A - Composiciones y métodos para la salud ocular que comprenden ácidos grasos de cadena muy larga. - Google Patents

Composiciones y métodos para la salud ocular que comprenden ácidos grasos de cadena muy larga.

Info

Publication number
MX2022011234A
MX2022011234A MX2022011234A MX2022011234A MX2022011234A MX 2022011234 A MX2022011234 A MX 2022011234A MX 2022011234 A MX2022011234 A MX 2022011234A MX 2022011234 A MX2022011234 A MX 2022011234A MX 2022011234 A MX2022011234 A MX 2022011234A
Authority
MX
Mexico
Prior art keywords
compositions
methods
long chain
chain fatty
fatty acids
Prior art date
Application number
MX2022011234A
Other languages
English (en)
Inventor
Daniel J Stein
Melinda Divito
Lester Hosten
Original Assignee
Bausch Lomb Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch Lomb Ireland Ltd filed Critical Bausch Lomb Ireland Ltd
Publication of MX2022011234A publication Critical patent/MX2022011234A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción describe composiciones que comprenden al menos un ácido graso de cadena muy larga elegido de ácidos C26+ (5n-3), profármacos de estos, y sales farmacéuticamente aceptables de cualquiera de los anteriores. Las composiciones son útiles en métodos para tratar afecciones asociadas con una pérdida de la agudeza visual lo que incluye, por ejemplo, degeneración macular relacionada con la edad.
MX2022011234A 2020-03-11 2021-03-11 Composiciones y métodos para la salud ocular que comprenden ácidos grasos de cadena muy larga. MX2022011234A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062988386P 2020-03-11 2020-03-11
US202063045609P 2020-06-29 2020-06-29
PCT/IB2021/052007 WO2021181311A1 (en) 2020-03-11 2021-03-11 Compositions and methods for eye health comprising very long chain fatty acids

Publications (1)

Publication Number Publication Date
MX2022011234A true MX2022011234A (es) 2022-12-13

Family

ID=74874917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011234A MX2022011234A (es) 2020-03-11 2021-03-11 Composiciones y métodos para la salud ocular que comprenden ácidos grasos de cadena muy larga.

Country Status (10)

Country Link
US (1) US20230124374A1 (es)
EP (1) EP4117652A1 (es)
JP (1) JP2023533633A (es)
KR (1) KR20220152237A (es)
CN (1) CN115551498A (es)
AU (1) AU2021235553A1 (es)
BR (1) BR112022018122A2 (es)
CA (1) CA3175005A1 (es)
MX (1) MX2022011234A (es)
WO (1) WO2021181311A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023100938A1 (ja) * 2021-12-03 2023-06-08 日本水産株式会社 酸化ストレス緩和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587391A1 (en) * 2004-11-16 2006-05-26 Nu-Tein Co., Inc. Compositions useful to treat ocular neovascular diseases and macular degeneration
EP1932521A1 (en) * 2006-12-15 2008-06-18 Novartis AG Nutritional supplement composition for treatment of ocular diseases
US20130190399A1 (en) * 2009-10-31 2013-07-25 Martek Biosciences Corporation Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)
US10633324B2 (en) * 2015-02-09 2020-04-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
JP2020514391A (ja) * 2017-03-20 2020-05-21 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジＢｏａｒｄ Ｏｆ Ｓｕｐｅｒｖｉｓｏｒｓ Ｏｆ Ｌｏｕｉｓｉａｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ａｎｄ Ａｇｒｉｃｕｌｔｕｒａｌ Ａｎｄ Ｍｅｃｈａｎｉｃａｌ Ｃｏｌｌｅｇｅ 超長鎖多価不飽和脂肪酸、エロバノイドヒドロキシル化誘導体、および使用方法
NO345574B1 (en) * 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis

Also Published As

Publication number Publication date
JP2023533633A (ja) 2023-08-04
KR20220152237A (ko) 2022-11-15
CA3175005A1 (en) 2021-09-16
EP4117652A1 (en) 2023-01-18
AU2021235553A1 (en) 2022-09-22
WO2021181311A1 (en) 2021-09-16
CN115551498A (zh) 2022-12-30
US20230124374A1 (en) 2023-04-20
BR112022018122A2 (pt) 2022-11-08

Similar Documents

Publication Publication Date Title
EP4353315A3 (en) Animal models, screening methods, and treatment methods for intraocular diseases or disorders
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
WO2006039327A3 (en) Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
MX337585B (es) Combinacion de componentes para la prevencion y el tratamiento de la debilidad.
MX2022011234A (es) Composiciones y métodos para la salud ocular que comprenden ácidos grasos de cadena muy larga.
WO2006055526A3 (en) Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2007011875A3 (en) Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
MX2022012079A (es) Metodos y composiciones para mantener la salud renal.
SG11201906169QA (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
WO2007046083A3 (en) Compositions for treatment of eye diseases
PH12019502886A1 (en) Methods for increasing growth of beneficial bacteria in the gastrointestinal tract
MX2020001404A (es) Dihidrooxadiazinonas.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
WO2008013986A3 (en) Compositions and methods for treating or preventing ophthalmic light toxicity
TW201628626A (zh) 水性點眼液
CL2017000867A1 (es) Composiciones de ácidos grasos y éster de ácido graso autoformadores de micelas y su uso en el tratamiento de patologías
MX2023006591A (es) Composiciones y metodos para el tratamiento de enfermedades oculares.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021007161A (es) Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia.
MX2020010477A (es) Composiciones y metodos para el tratamiento de la distrofia macular.
ATE508711T1 (de) Vorgeformter intrastromaler hornhauteinsatz für hornhautanomalien oder -dystrophien
EA201992356A1 (ru) Способ и композиция для лечения заболевания, связанного с сетчаткой глаза, с использованием ингибитора ccr3
MX2022001062A (es) Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
WO2020033867A3 (en) Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
MX2023003618A (es) Formas cristalinas de un compuesto farmaceutico.